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Follicular dendritic cell sarcoma (FDCS) is a rare intermediate
grade malignant neoplasm of reticular dendritic origin, first
described by Monda et al. in 1986.1 This entity frequently
develops in the lymph nodes of the cervical, axillary, and
supraclavicular region. The tonsil is one of the more common
extranodal sites that has been involved.2,3
Castleman’s disease (CD) represents a non-neoplastic
lymphoproliferative disorder with various clinical and mor-
phological features. Its clinicopathologic features depend
on various etiologic factors such as Kaposi sarcoma herpes-
virus, over secretion of IL-6, and follicular dendritic cell
dysplasia. Clinically, solitary Castleman’s disease presents
as a single mass, often in the mediastinum or the pulmonary741-9409/$ - see front matter c 2005 Elsevier Ltd. All rights reserved
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E-mail address: c.farah@uq.edu.au (C.S. Farah).hilum, and occurs in a young population. Generalized
involvement of nodes in several centers accompanied by
systemic involvement is manifested in the multicentric type
of Castleman’s disease.4
Approximately 22 of the 55 cases of follicular dendritic
cell sarcoma in the head and neck region that have been re-
ported to date have been extranodal.3,5 In the literature, 14
examples of FDCS have been reported to be associated with
Castleman’s disease.6 In this article, we describe the first
case of follicular dendritic cell sarcoma associated with
Castleman’s disease presenting in the oral cavity.Case report
A 62-year-old Caucasian female was referred in December
2003 for assessment of a soft tissue swelling in the right
maxillary buccal sulcus in the region of the missing 16.
The patient wore a complete maxillary acrylic denture,.
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mucosal ulceration which had previously resolved following
adjustment of the denture by her dentist. Her past medical
history was significant for osteoarthritis, one total knee
replacement, and a transient ischaemic attack.
Clinical examination confirmed the presence of a large
soft tissue mass measuring approximately 2.0 cm in greatest
dimension, located in the reflection of the sulcus in the 16
region. The lesion could not be visualized intra-orally or
extra-orally, but was easily palpable intra-orally. There
was no evidence of ulceration, or epithelial hyperplasia.
An incisional biopsy was performed under local anes-
thesia and microscopic examination revealed a lymphoid
nodule with a hyalinised connective tissue background.
Molecular analysis showed a monoclonal B-cell population
associated with a bcl-2 [t (14;18)] chromosome transloca-
tion, suggestive of an inconclusive presentation of follicular
lymphoma, although there were no constitutional symptoms
of lymphoma.
Subsequently, a deeper biopsy was performed one month
later on which extensive immunohistochemical and molecu-
lar studies were performed. Bcl-2 translocation was not de-
tected, and TCR gene rearrangement studies showed
polyclonal beta and gamma chains.
A working diagnosis of follicular dendritic cell sarcoma in
association with extranodal Castleman’s disease was made.
The patient was referred to the Oncology Clinic at the
Princess Alexandra Hospital, Brisbane, Australia. A CT and
MRI scan of the head and neck revealed a slightly lobulated
but well-defined right infra-temporal fossa mass lesion
marginating the anterior aspect of the right coronoid andFigure 1 MRI showing large mass lesion in right infra-
temporal fossa. The tumour appears to displace but not invade
adjacent structures. The mass measured approximately 4.5 cm
in the supero-inferior plane, 3.0 cm in the coronal plane, and
3.0 cm in the antero-posterior plane.mandibular ramus, with some erosion of the adjacent bone
(Fig. 1). The cortex was absent on the posterior zygoma, but
the tumour did not extend beyond its immediate margins.
There was no evidence of any involvement in the neck,
chest, abdomen or pelvis. There was no lymphadenopathy
or hepatosplenomegaly. A wide operative excision was per-
formed which included a close normal margin, and this was
followed with radiotherapy to the surgical site only. Nine
months later the patient presented with a submandibular
lymph node enlargement, which was confirmed on CT, and
she underwent subsequent irradiation to the ipsilateral
neck. The patient is now disease free.
Histopathologic examination
Haematoxylin and eosin stained sections revealed two mor-
phologically distinct areas. In one area, there were germinal
centres with prominent mantle zones, many of which con-
tained regressed follicles. Interfollicular sclerosis and lym-
phoid infiltrate were also evident (Fig. 2). The other
distinctive area of abnormality was a monomorphic spindle
cell proliferation containing admixed lymphocytes and scat-
tered plasma cells (Fig. 3).
Immunohistochemistry
The described lymphoid area of proliferation showed folli-
cles to be CD20+, CD79a+, CD3, CD43 and CD5 negative
within the follicles, but were positive within interfollicular
small regular lymphoid cells. The follicles showed weak pos-
itivity for CD10, but were negative for BCL-2. Kappa Lambda
stains showed apparent polyclonal cytoplasmic immuno-
globulin. BCL-6 was restricted to the germinal centres.
The spindle proliferation was strongly positive for CD21
(FDC marker) (Fig. 4). The spindle cell proliferation wasFigure 2 Castleman’s disease showing germinal centres with
prominent mantle zones, many of which contain regressed
follicles. Interfollicular sclerosis and lymphoid infiltrate are
also evident (H & E · 100).
Figure 3 Follicular dendritic cell sarcoma showing a mono-
morphic spindle cell proliferation containing admixed lympho-
cytes and scattered plasma cells. The tumour cells are arranged
in sheets with a whorled pattern, and are characteristically oval
or spindle shaped (H & E · 100).
Figure 4 Characteristic CD21 positivity of spindle prolifera-
tion of the follicular dendritic cell sarcoma (CD21 · 100).
96 C.S. Farah et al.negative for CD34, CD31, and SMA, but showed focal positiv-
ity for S-100.
Discussion
Follicular dendritic cell sarcomas primarily affect the young
or middle-aged adult with a median age of presentation of
43 years, with no gender predilection. In approximately
50% of cases, the lesion presents as a solitary, slow-growing,
and painless lymphadenopathy.7
Histologically, the neoplastic cells of FDCS display a char-
acteristic oval or spindle shape showing a syncytial and often
fibrillary cytoplasm. The nuclei are oval, with smooth con-
tours, vesicular or granular chromatin, and distinct nucleoli.They are arranged in sheets, interlacing fascicles, or stori-
form or whorled patterns. Two of the most characteristic
features of these neoplasms are the intimate admixture of
tumour cells and small lymphocytes throughout the tumour,
and the presence of perivascular lymphocytic cuffing.7,8
The pathologic diagnosis of FDCS is often challenging and
requires immunophenotyping as confirmatory, although
there is significant overlap with interdigitating dendritic cell
sarcoma. CD21 recognizes the C3d receptor and has been
demonstrated to be expressed in approximately 96% of
cases investigated.2,7 Variable expression is shown with
S-100 protein, EMA, CD68, MSA, and desmoplakin.
Rare cases of Castleman’s disease have been associated
with FDCS but no clonal correlation has been demonstrated.
In the literature, 14 examples of FDCS have been reported
to be associated with Castleman’s disease; the majority
involving the hyaline vascular (HV) type. The possible basis
of the association is the observed aberrations in FDC net-
works as well as FDC dysplasia in some follicles of Castle-
man’s disease.6 The presumption is that a FDC tumour
develops in Castleman’s disease through a hyperplasia–dys-
plasia–neoplasia sequence, similar to that documented for
epithelial neoplasms, however firm evidence of a clonal
relationship between Castleman’s and FDCS is scarce. Based
on all the documented cases, FDCS have arisen concomi-
tantly with or after a diagnosis of Castleman’s disease, sug-
gesting the existence of a pathogenetic link between these
conditions.6,7,9,10 It has been hypothesized that abnormali-
ties of FDC play a pivotal role in the pathogenesis of
Castleman’s disease of the hyaline vascular type.11
In cases that the two lesions were discovered in the same
anatomic site, it has been argued that the Castleman’s dis-
ease lesion was only a reaction to the FDC tumour rather
than a precursor lesion. On the contrary, Chan and col-
leagues clearly demonstrated, through three sequential
biopsies, the progression of FDC proliferation in the setting
of Castleman’s disease-HV.6 Additionally, they also found
some expression of p53 protein in the FDCS, and small
numbers of p53 positive cells in the interfollicular zone of
CD-HV, suggesting a role for this tumour suppressor gene
in the transformation process. In our case, we could not
demonstrate any evolution of FDCS from Castleman’s dis-
ease, and also can not exclude that the abnormalities of
FDCS play a pivotal role in the pathogenesis of Castleman’s
disease. There was also no evidence of any association of
Castleman’s disease with human herpes virus 8 (HHV8).
Spindle cell proliferation has been well documented with
Castleman’s disease.9 The spindle cell proliferation may
either be correlated to vascular proliferation or follicular
dendritic cell proliferation.4 In our case, the vascular mark-
ers were negative. Immunoglobulin heavy chain and T cell
receptor gene rearrangement studies showed a germline
configuration, providing no evidence for specific monoclonal
B or T lymphocyte differentiation. These results are in con-
cordance with genotypic studies performed in two other
cases.12,13
In summary, this report documents the first case of fol-
licular dendritic cell sarcoma occurring concomitantly with
Castleman’s disease presenting in the oral cavity. The find-
ing of these two distinct lymphoid processes within the
same lesion has become more recognizable, though rarely
arising within the oral cavity.
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